Intensifying control, simplifying treatment with Exforge-HCT®

Intensifying control, simplifying treatment with Exforge-HCT^®:

Triple therapy in once-daily single pill to control with more confidence

A patient in need of stronger and faster BP control

1 in 4

HTN patients need triple therapy to achieve BP control^1,2

4x

Meta-analysis: adding third drug lowered BP by 4 times than doubling dual therapy doses³

If BP remains uncontrolled after 3 months on maximum tolerable dual therapy, guidelines recommend intensifying to triple therapy to reduce CV risk and improve outcomes^4,5

Control with confidence — Exforge-HCT^® as the optimal intensive and simple choice for patients like Mr. Wei

Deliver powerful BP control
Exforge HCT^® delivers a powerful BP reduction for patients uncontrolled on dual therapy.⁶

Adapted from Braun N et al. 2009

Deliver powerful BP control
Exforge HCT^® ensures BP control for patients with different HTN severities and CVD risk.^7-10

Proven safety and tolerability profile
Exforge HCT^® offers a safety and tolerability profile similar to dual therapy, in both RCT and real-world settings.^11-13

Exforge HCT® (ARB + CCB + HCT) delivers a reliable and sustainable control¹⁴

Abbreviations:
ACE, angiotensin-converting enzyme; ARBs, Angiotensin Receptor Blockers; BP, blood pressure; CCB, Calcium Channel Blockers; CVD, cardiovascular diseases; HCT, Hydrochlorothiazide; HTN, hypertension; ISH, Isolated Systolic Hypertension; RCT, Randomized Controlled Trial; SPC, single-pill combination.

References:
1. Zaman MA, et al. Cureus. 2023;15(7):e41398. 2. Volpe M, et al. Trends Cardiovasc Med. 2020;30(2):72-77. 3. Salam A, et al. J Hypertens. 2019;37(8):1567-1573. 4. Mancia G, et al. J Hypertens. 2023;41(12):1874-2071. 5. McEvoy JW, et al. Eur Heart J. 2024;45(38):3912-4018. 6. Braun N, et al. Poster presented at: Congress of the German Society for Internal Medicine (DGIM); 21 April 2009; Wiesbaden, Germany. 7. Calhoun DA et al. Adv Ther 2009; 26(11): 1012-1023. 8. Calhoun DA et al. Hypertension 2009; 54(1): 32-39. 9. Destro M et al. Vasc Health Risk Manag 2010; 6: 821-827. 10. Assaad-Khalil SH et al. Vasc Health Risk Manag 2015; 11: 71-78. 11. Sison J et al. Curr Med Res Opin 2014; 30: 1937-1945. 12. Assaad-Khalil SH et al. Vasc Health Risk Manag 2015; 11: 71-78. 13. Hagendorff A et al. J Drug Assess 2014; 3: 1-9. 14. Machnicki G et al. Curr Med Res Opin. 2015;31(12):2287-2296.

20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439

Phone: +65 6722 6010

FOR HEALTHCARE PROFESSIONALS ONLY

APPROVAL CODE

×

Medical Information Request

Ask Speakers